Skip to main content

What the FDA labels say about taking them together

Ivabradine and siponimod

Siponimod's FDA label of June 30, 2026 names ivabradine in its drug interactions section; the ivabradine label PlainMeds reads does not name siponimod. The siponimod label: “Experience with MAYZENT is limited in patients receiving concurrent therapy with drugs that decrease heart rate.”

Check it at the source: the ivabradine FDA label on DailyMed (effective November 10, 2025); the siponimod FDA label on DailyMed (effective June 30, 2026, Novartis Pharmaceuticals Corporation).

What does the ivabradine label say about siponimod?

Ivabradine's label (effective November 10, 2025) does not name siponimod in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Corlanor), Amgen Inc, effective November 10, 2025 (SPL set 92018a65-38f6-45f7-91d4-a34921b81d0d), via openFDA; the full label on DailyMed

What does the siponimod label say about ivabradine?

Siponimod label, drug interactions

Because of the potential additive effects on heart rate, treatment with MAYZENT should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties, heart-rate lowering calcium channel blockers (e.g., verapamil, diltiazem), or other drugs that may decrease heart rate (e.g., ivabradine, digoxin) [see Warnings and Precautions (5.4) and Drug Interactions (7.3)].

Siponimod label, warnings and precautions

Experience with MAYZENT is limited in patients receiving concurrent therapy with drugs that decrease heart rate (e.g., beta-blockers, calcium channel blockers - diltiazem and verapamil, and other drugs that may decrease heart rate, such as ivabradine and digoxin).

Source: FDA drug label (MAYZENT), Novartis Pharmaceuticals Corporation, effective June 30, 2026 (SPL set 44492772-5aed-4627-bd85-e8e89f308bb3), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

11Ivabradine generic labelers
0Siponimod generic labelers
IvabradineSiponimod
Labeled forHeart failureMultiple sclerosis
Boxed warningNoNo
Pharmacy cost (NADAC)$0.761 per tablet 5 mg tabletn/a
Shortage nowA presentation being discontinuedNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?